Follow the people · Insider
Christine Mikail Cvijic
Christine Mikail Cvijic files insider transactions with the SEC as a president and cfo of Neurogene (NGNE). We hold 8 disclosed purchases and sales filed since 12 March 2012, 4 of them in the last 90 days.
- Files forNGNE
- Disclosed buys and sells8 in all, 4 in the last 90 days
- Last disclosure7 July 2026
Positions held
4 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 13 March 2024 — 7 July 2026President and CFO · Neurogene (NGNE)27 Form 4 lines · source: SEC Form 4
- Filed 29 April 2016 — 29 April 2016Chief Admin Officer and GC · Axovant Sciences (AXON)1 Form 4 line · source: SEC Form 4
- Filed 15 April 2014 — 21 February 2015SVP, Legal Affairs & GC · Nps Pharmaceuticals (NPSP)6 Form 4 lines · source: SEC Form 4
- Filed 8 March 2012 — 10 February 2014EVP, Corp Dev, Gen Cnsl/Scrtry · Dendreon (DNDN)11 Form 4 lines · source: SEC Form 4
Everything they disclosed
45 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 600 shares of NeurogeneSEC Form 47 July 2026Common Stock · traded 6 July 2026 · filed 7 July 2026
- ▼ sold on the open market 4,200 shares of NeurogeneSEC Form 47 July 2026Common Stock · traded 7 July 2026 · filed 7 July 2026
- ▼ sold on the open market 739 shares of NeurogeneSEC Form 42 July 2026Common Stock · traded 1 July 2026 · filed 2 July 2026
- ▼ sold on the open market 2,531 shares of NeurogeneSEC Form 42 July 2026Common Stock · traded 2 July 2026 · filed 2 July 2026
- ▼ sold on the open market 1,530 shares of NeurogeneSEC Form 42 July 2026Common Stock · traded 2 July 2026 · filed 2 July 2026
- ▼ sold on the open market 4,800 shares of NeurogeneSEC Form 48 May 2026Common Stock · traded 6 May 2026 · filed 8 May 2026
- ▼ sold on the open market 4,800 shares of NeurogeneSEC Form 48 May 2026Common Stock · traded 6 May 2026 · filed 8 May 2026
- ▼ sold on the open market 2,558 shares of NeurogeneSEC Form 430 March 2026Common Stock · traded 26 March 2026 · filed 30 March 2026
- ▼ sold on the open market 2,558 shares of NeurogeneSEC Form 430 March 2026Common Stock · traded 26 March 2026 · filed 30 March 2026
- ▼ sold on the open market 2,387 shares of NeurogeneSEC Form 417 March 2026Common Stock · traded 13 March 2026 · filed 17 March 2026
- ▼ sold on the open market 1,395 shares of NeurogeneSEC Form 417 March 2026Common Stock · traded 13 March 2026 · filed 17 March 2026
- ▼ sold on the open market 263 shares of NeurogeneSEC Form 417 March 2026Common Stock · traded 13 March 2026 · filed 17 March 2026
- ▼ sold on the open market 2,387 shares of NeurogeneSEC Form 417 March 2026Common Stock · traded 13 March 2026 · filed 17 March 2026
- ▼ sold on the open market 1,395 shares of NeurogeneSEC Form 417 March 2026Common Stock · traded 13 March 2026 · filed 17 March 2026
- ▼ sold on the open market 263 shares of NeurogeneSEC Form 417 March 2026Common Stock · traded 13 March 2026 · filed 17 March 2026
- ▼ sold on the open market 4,800 shares of NeurogeneSEC Form 43 March 2026Common Stock · traded 27 February 2026 · filed 3 March 2026
- ▼ sold on the open market 4,800 shares of NeurogeneSEC Form 43 March 2026Common Stock · traded 27 February 2026 · filed 3 March 2026
- was granted 22,000 shares of NeurogeneSEC Form 424 February 2026Common Stock · traded 20 February 2026 · filed 24 February 2026
- was granted 131,900 shares of Neurogene (a derivative holding)SEC Form 424 February 2026Stock Option (Right to Buy) · traded 20 February 2026 · filed 24 February 2026
- was granted 131,900 shares of Neurogene (a derivative holding)SEC Form 424 February 2026Stock Option (Right to Buy) · traded 20 February 2026 · filed 24 February 2026
- was granted 22,000 shares of NeurogeneSEC Form 424 February 2026Common Stock · traded 20 February 2026 · filed 24 February 2026
- was granted 122,000 shares of Neurogene (a derivative holding)SEC Form 428 March 2025Employee Stock Option (Right to buy) · traded 26 March 2025 · filed 28 March 2025
- was granted 20,300 shares of NeurogeneSEC Form 428 March 2025Common Stock · traded 26 March 2025 · filed 28 March 2025
- ▼ sold on the open market 4,501 shares of NeurogeneSEC Form 417 March 2025Common Stock · traded 13 March 2025 · filed 17 March 2025
- ▲ bought on the open market 24,000 shares of NeurogeneSEC Form 425 November 2024Common Stock · traded 22 November 2024 · filed 25 November 2024
- was granted 53,900 shares of Neurogene (a derivative holding)SEC Form 414 March 2024Employee Stock Option (Right to buy) · traded 13 March 2024 · filed 14 March 2024
- was granted 31,903 shares of NeurogeneSEC Form 414 March 2024Common Stock · traded 13 March 2024 · filed 14 March 2024
- was granted 50,000 shares of Axovant Sciences (a derivative holding)SEC Form 43 May 2016Employee Stock Option (Right to Buy) · traded 29 April 2016 · filed 3 May 2016
- returned to the issuer 79,453 shares of Nps Pharmaceuticals (a derivative holding)SEC Form 424 February 2015Stock Options (right to buy) · traded 21 February 2015 · filed 24 February 2015
- returned to the issuer 10,905 shares of Nps Pharmaceuticals (a derivative holding)SEC Form 424 February 2015Restricted Stock Units · traded 21 February 2015 · filed 24 February 2015
- returned to the issuer 29,085 shares of Nps Pharmaceuticals (a derivative holding)SEC Form 424 February 2015Restricted Stock Units · traded 21 February 2015 · filed 24 February 2015
- was granted 10,905 shares of Nps Pharmaceuticals (a derivative holding)SEC Form 420 February 2015Restricted Stock Units · traded 12 February 2015 · filed 20 February 2015
- was granted 79,453 shares of Nps Pharmaceuticals (a derivative holding)SEC Form 417 April 2014Employee Stock Option (right to buy) · traded 15 April 2014 · filed 17 April 2014
- was granted 29,085 shares of Nps Pharmaceuticals (a derivative holding)SEC Form 417 April 2014Restricted Stock Units · traded 15 April 2014 · filed 17 April 2014
- was granted 17,956 shares of DendreonSEC Form 412 February 2014Common Stock · traded 10 February 2014 · filed 12 February 2014
- had shares withheld for tax on 6,167 shares of DendreonSEC Form 412 February 2014Common Stock · traded 10 February 2014 · filed 12 February 2014
- was granted 200,000 shares of DendreonSEC Form 47 January 2014Common Stock · traded 3 January 2014 · filed 7 January 2014
- had shares withheld for tax on 9,456 shares of DendreonSEC Form 47 January 2014Common Stock · traded 3 January 2014 · filed 7 January 2014
- had shares withheld for tax on 1,380 shares of DendreonSEC Form 410 December 2013Common Stock · traded 8 December 2013 · filed 10 December 2013
- had shares withheld for tax on 1,380 shares of DendreonSEC Form 49 September 2013Common Stock · traded 8 September 2013 · filed 9 September 2013
- had shares withheld for tax on 1,380 shares of DendreonSEC Form 410 June 2013Common Stock · traded 8 June 2013 · filed 10 June 2013
- had shares withheld for tax on 5,520 shares of DendreonSEC Form 412 March 2013Common Stock · traded 8 March 2013 · filed 12 March 2013
- was granted 94,502 shares of DendreonSEC Form 47 January 2013Common Stock · traded 3 January 2013 · filed 7 January 2013
- was granted 128,580 shares of Dendreon (a derivative holding)SEC Form 412 March 2012Non-Qualified Stock Option (right to buy) · traded 8 March 2012 · filed 12 March 2012
- was granted 64,290 shares of DendreonSEC Form 412 March 2012Common Stock · traded 8 March 2012 · filed 12 March 2012
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.